Evidence map›Paper›PMID 34202223›Full record

ReviewInternational journal of molecular sciences2021

Complement System and Potential Therapeutics in Age-Related Macular Degeneration.

Young Gun Park, Yong Soo Park, In-Beom Kim

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 2 pooled it
7.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 2 syntheses or guidelines pooled it, 48 citations in OpenAlex.

  1. Pooled it
  2. Vitamin D and Ocular Diseases: A Systematic Review.International journal of molecular sciences · 2022
    Pooled it
  3. Trial
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Recent Updates on the Diagnosis and Management of Age-Related Macular Degeneration.Mayo Clinic proceedings. Innovations, quality & outcomes · 2024
    Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Young Gun ParkDepartment of Ophthalmology and Visual Science, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea.
Yong Soo ParkDepartment of Anatomy, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea.ORCID 0000-0001-8416-0949
In-Beom KimDepartment of Anatomy, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea.ORCID 0000-0002-1932-8407
The Catholic University of Korea Seoul St. Mary's Hospital · KRCatholic University of Korea · KR

Funding

National Research Foundation of Korea 2017R1A2B2005309
6 · The paper itself

Abstract

Age-related macular degeneration (AMD) is a complex multifactorial disease characterized in its late form by neovascularization (wet type) or geographic atrophy of the retinal pigment epithelium cell layer (dry type). The complement system is an intrinsic component of innate immunity. There has been growing evidence that the complement system plays an integral role in maintaining immune surveillance and homeostasis in AMD. Based on the association between the genotypes of complement variants and AMD occurrence and the presence of complement in drusen from AMD patients, the complement system has become a therapeutic target for AMD. However, the mechanism of complement disease propagation in AMD has not been fully understood. This concise review focuses on an overall understanding of the role of the complement system in AMD and its ongoing clinical trials. It provides further insights into a strategy for the treatment of AMD targeting the complement system.

Indexed as

Clinical Trials as TopicComplement ActivationComplement System ProteinsDiagnostic ImagingDisease ManagementDisease SusceptibilityHumansMacular DegenerationMolecular Targeted TherapyRisk FactorsTreatment OutcomeComplement System Proteinsage-related macular degenerationclinical trialcomplement cascadetherapeutics

Identifiers

PMID34202223
PMCPMC8269056
OpenAlexW3173766535

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.